The Complete Blood Work Guide for TRT

Why does blood work matter on TRT?

Blood work is the single most important tool for managing testosterone replacement therapy safely. Without regular lab monitoring, you and your provider are guessing — about your dose, your estrogen balance, your red blood cell count, and whether your body is responding to treatment the way it should. According to the Endocrine Society's 2018 clinical practice guidelines, regular laboratory monitoring is essential for all men on testosterone therapy to assess therapeutic response and detect adverse effects.

TRT shifts multiple systems at once. Testosterone converts to estradiol via aromatase. It stimulates erythropoiesis, increasing red blood cell production. It affects lipid metabolism, liver function, and prostate-specific antigen levels. Each of these changes has a clinically relevant range — and each requires its own lab marker to track.

The consequences of skipping blood work go beyond suboptimal results. Unchecked hematocrit elevation increases blood viscosity and cardiovascular risk. Unmonitored estradiol can cause gynecomastia, water retention, and mood instability. A rising PSA without monitoring could delay detection of prostate issues. Regular blood work catches these problems early, while they are still easy to correct with simple protocol adjustments.

This guide covers every marker you need to understand — whether you are considering TRT, just starting, or years into therapy. We will walk through what each marker measures, what the optimal ranges are for men on TRT (not just the reference ranges printed on lab reports), and how to build a monitoring schedule that keeps you safe without overtesting.

What are the essential lab markers for TRT?

A complete TRT monitoring panel covers hormones, blood cell counts, metabolic health, and organ function. The American Urological Association (AUA) and the Endocrine Society both recommend a core set of markers, though individual providers may add tests based on your health history. Here is the complete breakdown.

How are total, free, and bioavailable testosterone different?

Testosterone circulates in three forms: roughly 2% as free (unbound) testosterone, 38% loosely bound to albumin, and 60% tightly bound to sex hormone-binding globulin (SHBG). Total testosterone measures all three forms combined. Free testosterone measures only the unbound fraction. Bioavailable testosterone includes both free testosterone and the albumin-bound portion, since albumin releases testosterone easily at the tissue level.

For most men, total testosterone is sufficient for monitoring TRT. However, when SHBG is elevated — due to aging, liver conditions, hyperthyroidism, or certain medications — total testosterone can appear normal while free testosterone is low. In these cases, free testosterone provides a more accurate picture of what your body can actually use. The Endocrine Society recommends measuring free testosterone when total testosterone is borderline or when SHBG abnormalities are suspected.

Free testosterone can be measured directly (equilibrium dialysis is the gold standard) or calculated using total testosterone, SHBG, and albumin values. Calculated free testosterone is reliable when quality assays are used for the inputs. Direct immunoassay methods for free T are less accurate and should generally be avoided.

For a deeper dive into interpreting these numbers and understanding what drives the difference, read our full guide on total vs. free testosterone.

What role does estradiol play on TRT?

Estradiol (E2) is the most potent form of estrogen and plays a critical role in men's health — even though it is commonly associated with female physiology. In men, estradiol supports bone density, cardiovascular function, libido, and cognitive health. Testosterone converts to estradiol through the aromatase enzyme, primarily in adipose (fat) tissue.

When you start TRT or increase your dose, estradiol typically rises in proportion. This is a normal physiological response. Problems arise when estradiol goes too high (causing water retention, mood swings, gynecomastia, or erectile difficulty) or is suppressed too low by aggressive use of aromatase inhibitors (causing joint pain, low libido, fatigue, and bone density loss).

The target range for estradiol on TRT is generally 20-40 pg/mL when measured with a sensitive (LC-MS/MS) assay. The standard immunoassay estradiol test designed for women is less accurate for the lower levels typical in men — always request the sensitive assay. Managing estradiol is about finding balance, not driving it as low as possible.

For a complete breakdown of estradiol management, symptoms of high and low E2, and the evidence on aromatase inhibitor use, see our guide on estradiol levels on TRT.

Why do hematocrit and hemoglobin matter on TRT?

Hematocrit measures the percentage of your blood volume occupied by red blood cells. Hemoglobin is the oxygen-carrying protein inside those cells. Testosterone is a potent stimulator of erythropoiesis (red blood cell production), which is why TRT reliably increases both hematocrit and hemoglobin — typically by 3-5% for hematocrit over the first 6-12 months of therapy.

This is the most common side effect of TRT. A 2017 meta-analysis published in The Journal of Clinical Endocrinology & Metabolism found that erythrocytosis (hematocrit above 54%) occurred in approximately 12% of men on injectable testosterone. Higher doses, injectable routes (versus topical), and individual genetic variation all increase the risk.

Elevated hematocrit increases blood viscosity, which raises the risk of thromboembolic events including stroke and deep vein thrombosis. The Endocrine Society recommends checking hematocrit at baseline, 3-6 months after starting TRT, and at least annually thereafter. If hematocrit exceeds 54%, guidelines recommend reducing the dose, switching delivery methods, or performing therapeutic phlebotomy (blood donation).

For strategies on managing hematocrit and when to take action, read our full guide on hematocrit management on TRT.

How does TRT affect PSA and prostate health?

Prostate-specific antigen (PSA) is a protein produced by the prostate gland. PSA levels are used as a screening marker for prostate issues, including benign prostatic hyperplasia (BPH) and prostate cancer. Testosterone and its more potent metabolite dihydrotestosterone (DHT) stimulate prostate tissue, which is why PSA monitoring is standard practice during TRT.

Here is what the evidence actually shows: TRT typically causes a modest PSA increase of 0.3-0.5 ng/mL within the first 6-12 months, then stabilizes. A large-scale 2016 meta-analysis in The Journal of Urologyanalyzing over 5,000 men found no statistically significant increase in prostate cancer risk among men receiving testosterone therapy. The AUA's 2018 guidelines state that TRT does not appear to increase the risk of prostate cancer in men without a prior history of the disease.

That said, monitoring remains essential. A rapid PSA rise (velocity greater than 0.75 ng/mL per year) or an absolute value above 4.0 ng/mL warrants further evaluation, including potential referral to a urologist. Men with a history of prostate cancer should discuss TRT risks individually with their oncologist and urologist.

For the full evidence review on prostate safety and monitoring protocols, see our PSA and TRT guide.

Which metabolic and lipid markers should you track?

TRT affects metabolic health in several ways, and a standard lipid panel plus comprehensive metabolic panel (CMP) captures the important changes. The lipid panel measures total cholesterol, LDL, HDL, and triglycerides. The CMP covers liver enzymes (AST, ALT), kidney function (BUN, creatinine), fasting glucose, and electrolytes.

Testosterone's effect on lipids is nuanced. TRT tends to slightly decrease HDL cholesterol (the “good” cholesterol) — a well-documented effect, particularly with injectable formulations. A 2018 systematic review found that intramuscular testosterone reduced HDL by an average of 3-5 mg/dL. Effects on LDL and triglycerides are variable and generally small. The clinical significance of this HDL reduction is debated, since TRT simultaneously improves body composition, insulin sensitivity, and visceral fat — all independent cardiovascular risk factors.

Liver enzymes (AST, ALT) should be monitored because oral testosterone formulations — specifically the older 17-alpha-alkylated compounds and the newer oral testosterone undecanoate — can stress the liver. Injectable and transdermal testosterone do not carry significant hepatotoxicity risk, but baseline and periodic liver panels are still standard practice.

Fasting glucose and HbA1c are worth tracking because testosterone improves insulin sensitivity in many men. If you are diabetic or pre-diabetic, TRT may reduce your glucose levels enough to require medication adjustments — a positive effect, but one that needs monitoring.

Why should you check thyroid and other hormones?

Hypothyroidism and hypogonadism share many symptoms: fatigue, weight gain, brain fog, low libido, and depressed mood. A pre-TRT thyroid panel (at minimum, TSH and free T4) rules out thyroid dysfunction as the cause — or co-contributor — of your symptoms. Starting TRT without checking thyroid function can lead to partial symptom relief and a missed diagnosis.

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are essential for the pre-TRT workup but less useful once you are on therapy. LH and FSH tell your provider whether low testosterone is primary (testicular failure — LH/FSH will be elevated) or secondary (pituitary/hypothalamic issue — LH/FSH will be low or normal). This distinction matters for treatment planning, since secondary hypogonadism may respond to alternative therapies like clomiphene citrate, while primary hypogonadism typically requires TRT directly.

Prolactin should be checked at baseline. Elevated prolactin can suppress GnRH, lowering testosterone production. A significantly elevated prolactin level may indicate a pituitary adenoma requiring imaging. Once on TRT, prolactin does not need routine monitoring unless symptoms suggest elevation (gynecomastia, galactorrhea, visual changes).

DHEA-S, cortisol, and insulin may be added to a comprehensive panel depending on your clinical picture. These markers help characterize adrenal function and metabolic health more broadly but are not universally required for TRT monitoring.

What is SHBG and why does it affect your testosterone levels?

Sex hormone-binding globulin (SHBG) is a protein produced primarily by the liver that binds testosterone with high affinity. Approximately 60% of circulating testosterone is bound to SHBG, rendering it biologically inactive — it cannot enter cells or activate androgen receptors while attached. Understanding your SHBG level is essential for interpreting testosterone blood work accurately.

High SHBG binds more testosterone, reducing the free fraction available to tissues. This means a man with a total testosterone of 600 ng/dL and high SHBG may have less biologically available testosterone than a man at 450 ng/dL with low SHBG. Conditions that raise SHBG include aging, liver disease, hyperthyroidism, low caloric intake, and certain medications (particularly anticonvulsants and some antidepressants).

Low SHBG allows more free testosterone but may also increase estradiol conversion. Obesity, insulin resistance, type 2 diabetes, and hypothyroidism are associated with lower SHBG levels. On TRT, exogenous testosterone tends to lower SHBG modestly, which is one reason free testosterone often rises proportionally more than total testosterone after starting therapy.

SHBG also influences injection frequency decisions. Men with low SHBG metabolize testosterone faster and may benefit from more frequent injections (every other day or three times weekly) to maintain stable levels. For a full explanation, see our dedicated guide on SHBG and testosterone.

What should your pre-TRT baseline panel include?

The pre-TRT panel is the most comprehensive blood draw you will do. Its purpose is threefold: confirm the diagnosis of hypogonadism, rule out secondary causes, and establish baseline values for markers that TRT will change. The Endocrine Society requires at least two morning testosterone measurements below the lower limit of normal (generally 300 ng/dL) before initiating therapy.

Core pre-TRT panel

• Total testosterone — two separate morning draws (before 10 AM), fasting
• Free testosterone — especially if SHBG is elevated or total T is borderline
• Estradiol, sensitive (LC-MS/MS) — baseline for comparison during treatment
• LH and FSH — distinguish primary from secondary hypogonadism
• Prolactin — rule out prolactinoma as a cause of low T
• SHBG — context for total vs. free testosterone interpretation
• CBC with differential — includes hematocrit and hemoglobin baseline
• Comprehensive metabolic panel (CMP) — liver and kidney function baseline
• Lipid panel — fasting cholesterol, LDL, HDL, triglycerides
• TSH and free T4 — rule out thyroid dysfunction
• PSA — required baseline for men 40 and older; recommended for younger men with family history
• HbA1c or fasting glucose — metabolic health baseline

Some providers add DHEA-S, cortisol (morning draw), vitamin D, and ferritin to the initial workup. These are not universally required but provide useful context. Vitamin D deficiency, for example, is associated with lower testosterone and may be worth addressing alongside TRT.

For a step-by-step walkthrough of ordering and interpreting your first panel, see our pre-TRT blood panel guide.

How often should you get blood work on TRT?

The monitoring schedule for TRT follows a front-loaded pattern: more frequent testing early on, then tapering to less frequent checks once your protocol is stable. The Endocrine Society and AUA guidelines provide a clear framework.

First-year monitoring schedule

Ongoing monitoring after year one

Once your levels are stable and you have been on the same dose for at least six months without issues, most providers shift to testing every 6-12 months. Hematocrit should be checked at every lab draw regardless of stability. PSA should be checked annually for men over 40. If you change your dose, switch delivery methods, or experience new symptoms, reset to the initial monitoring schedule (recheck at 6-8 weeks post-change).

For a more detailed month-by-month breakdown with specific recommendations for each delivery method, read our dedicated guide on blood work frequency on TRT.

How do you read your TRT lab results?

Lab reports include a reference range for each marker — the range that covers approximately 95% of the “healthy” population tested by that laboratory. These ranges are useful as a starting point but have significant limitations for men on TRT.

Reference range vs. optimal range

The total testosterone reference range at most labs is 264-916 ng/dL or 300-1,000 ng/dL, depending on the laboratory and assay. This range includes men of all ages — meaning the lower end reflects levels common in men over 70. A 35-year-old man at 310 ng/dL is technically “in range” but is at the level typical for a man decades older.

Most TRT-focused clinicians target levels that correlate with symptom resolution rather than just clearing the lower reference limit. For total testosterone, this is typically 600-900 ng/dL at trough. For free testosterone, 15-25 ng/dL or the upper quartile of the reference range is a common target.

Timing affects your numbers

When you draw blood relative to your injection schedule matters enormously for injectable testosterone. Most providers want a trough level — blood drawn the morning of your next scheduled injection, before you inject. This captures your lowest point and ensures your minimum level is adequate. Drawing at peak (24-48 hours after injection with cypionate/enanthate) will show numbers 30-50% higher than trough and can be misleading if your provider does not know when the draw occurred.

For transdermal testosterone (gels, creams, patches), blood should generally be drawn 2-4 hours after application for peak assessment, or before application for trough. Your provider will specify which they want based on your clinical situation.

Trends matter more than single values

A single lab result is a snapshot. Trends across multiple draws reveal the real story. A hematocrit of 50% that has been stable for two years is different from a hematocrit of 50% that was 44% three months ago. Always compare your current results to your baseline and recent prior values. Bring previous lab reports to appointments or keep them organized in a personal spreadsheet.

Where can you get TRT blood work done?

You have several options for getting TRT-related blood work, each with different cost structures, convenience levels, and turnaround times. The right choice depends on whether you have a provider ordering labs, whether you have insurance, and which state you live in.

Direct-to-consumer lab ordering is available in most US states, but a few states (New York, New Jersey, and Rhode Island) restrict it. In those states, you need a provider order. Many online platforms will connect you with a provider who can place the order if you do not have one.

For a detailed comparison of platforms, pricing, and tips for getting the most value from your labs, see our full guide on where to get testosterone tested.

What are the most common blood work mistakes on TRT?

Even experienced TRT patients make avoidable errors with their blood work. These mistakes can lead to inaccurate results, unnecessary dose changes, or missed warning signs. Here are the most frequent ones and how to avoid them.

Drawing blood at the wrong time

This is the most common mistake. Testosterone follows a diurnal pattern, peaking in the early morning. For diagnostic purposes (pre-TRT), blood must be drawn before 10 AM. On injectable TRT, drawing at peak instead of trough overstates your effective level and may prompt an unnecessary dose reduction. Always confirm with your provider whether they want a trough, mid-cycle, or peak measurement.

Ordering the wrong estradiol test

The standard estradiol immunoassay (ECLIA) is calibrated for female ranges and is unreliable at the lower concentrations typical in men. The sensitive estradiol assay using LC-MS/MS (liquid chromatography-tandem mass spectrometry) is accurate across the full male range. When ordering labs — especially through direct-to-consumer platforms — make sure the panel specifies “estradiol, sensitive” or “estradiol by LC-MS/MS.”

Not fasting when needed

If your panel includes a lipid profile or fasting glucose, eating before your draw will skew triglycerides and glucose upward. Fast for 8-12 hours before a morning draw. Water, black coffee without sugar, and prescribed medications are generally fine — but check with your lab for specifics.

Fixating on a single result instead of trends

A one-time hematocrit of 51% does not necessarily mean you need to donate blood. It could reflect dehydration, lab variability, or altitude. Compare it to your previous draws. If it has been creeping upward over three consecutive labs — from 46% to 49% to 51% — that trend warrants action even though none of the individual values cross the 54% threshold.

Skipping the baseline panel

Starting TRT without baseline blood work means you have no reference point for comparison. If your hematocrit is 52% six months into TRT, is that a problem? Without knowing whether you started at 48% (small increase) or 44% (significant increase), you and your provider cannot make informed decisions. The pre-TRT panel is non-negotiable.

Dive deeper into specific markers

This pillar guide covers the full landscape of TRT blood work. For detailed, marker-specific guidance, explore our spoke articles:

• Total vs. Free Testosterone: What the Numbers Mean
• Estradiol on TRT: Managing Estrogen Levels
• Hematocrit on TRT: Monitoring and Management
• Pre-TRT Blood Panel: What to Order and Why
• SHBG Explained: How It Affects Your Testosterone
• How Often Should You Get Blood Work on TRT?
• PSA and TRT: Prostate Safety and Monitoring
• Where to Get Testosterone Tested